ESMO 2020 | Standard-dose vs. high-dose thoracic radiotherapy in limited stage SCLC

Bjørn H Grønberg, MD, PhD, NTNU, Norwegian University of Science and Technology, and St. Olav’s Hospital, Trondheim University Hospital, Trondheim, Norway, outlines patient-reported outcomes from a randomized Phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small cell lung cancer (SCLC). Dr Grønberg discusses the results of quality-of-life endpoints evaluated in this study, including dyspnea, dysphagia and fiscal burdens. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).